RTKN Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant RTKN.
|Application ||WB, IHC, E|
|Calculated MW||62667 Da|
|Other Names||Rhotekin, RTKN (HGNC:10466), RTKN1|
|Target/Specificity||RTKN (NP_149035, 451 a.a. ~ 549 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||RTKN Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a scaffold protein that interacts with GTP-bound Rho proteins. Binding of this protein inhibits the GTPase activity of Rho proteins. This protein may interfere with the conversion of active, GTP-bound Rho to the inactive GDP-bound form by RhoGAP. Rho proteins regulate many important cellular processes, including cytokinesis, transcription, smooth muscle contraction, cell growth and transformation. Dysregulation of the Rho signal transduction pathway has been implicated in many forms of cancer. Alternative splicing results in multiple transcript variants encoding different isoforms.
Semaphorin 4D signaling requires the recruitment of phospholipase C gamma into the plexin-B1 receptor complex. Swiercz JM, et al. Mol Cell Biol, 2009 Dec. PMID 19805522.miR-145 inhibits breast cancer cell growth through RTKN. Wang S, et al. Int J Oncol, 2009 May. PMID 19360360.Interaction of a multi-domain adaptor protein, vinexin, with a Rho-effector, Rhotekin. Nagata K, et al. Med Mol Morphol, 2009 Mar. PMID 19294487.ACF7 regulates cytoskeletal-focal adhesion dynamics and migration and has ATPase activity. Wu X, et al. Cell, 2008 Oct 3. PMID 18854161.SEPT9 sequence alternations causing hereditary neuralgic amyotrophy are associated with altered interactions with SEPT4/SEPT11 and resistance to Rho/Rhotekin-signaling. Sudo K, et al. Hum Mutat, 2007 Oct. PMID 17546647.
If you have any additional inquiries please email technical services at email@example.com.